CR20190131A - 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso - Google Patents
1-arilnaftiridin-3-carboxamidas 7-sustituidas y su usoInfo
- Publication number
- CR20190131A CR20190131A CR20190131A CR20190131A CR20190131A CR 20190131 A CR20190131 A CR 20190131A CR 20190131 A CR20190131 A CR 20190131A CR 20190131 A CR20190131 A CR 20190131A CR 20190131 A CR20190131 A CR 20190131A
- Authority
- CR
- Costa Rica
- Prior art keywords
- para
- diseases
- naphthyridine
- aryl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188728.6A EP3296298A1 (de) | 2016-09-14 | 2016-09-14 | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| EP16202509 | 2016-12-06 | ||
| PCT/EP2017/072339 WO2018050510A1 (de) | 2016-09-14 | 2017-09-06 | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190131A true CR20190131A (es) | 2019-05-15 |
Family
ID=59966701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190131A CR20190131A (es) | 2016-09-14 | 2017-09-06 | 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso |
Country Status (40)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20180252A1 (es) | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
| US10519154B2 (en) | 2016-07-11 | 2019-12-31 | Bayer Pharma Aktiengesellschaft | 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| WO2021204701A1 (en) * | 2020-04-08 | 2021-10-14 | Bayer Aktiengesellschaft | Rapid detection of viral infection using rt-pcr |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| JPS60228479A (ja) | 1984-04-26 | 1985-11-13 | Toyama Chem Co Ltd | １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩 |
| DE3508816A1 (de) | 1985-01-10 | 1986-07-10 | Bayer Ag, 5090 Leverkusen | 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren |
| DE3906365A1 (de) * | 1988-07-15 | 1990-01-18 | Bayer Ag | 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe |
| DE4301246A1 (de) | 1993-01-19 | 1994-07-21 | Bayer Ag | Chinolon- und Naphthyridoncarbonsäurederivate |
| CA2168764C (en) * | 1993-08-13 | 2000-01-18 | Sung June Yoon | Novel quinolone carboxylic acid derivatives |
| WO1998023592A1 (fr) | 1996-11-28 | 1998-06-04 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'acide pyridonecarboxylique ou leurs sels, et medicaments contenant ceux-ci en tant que principe actif |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| US6964966B2 (en) | 2001-04-25 | 2005-11-15 | Wockhardt Limited | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| EP1453824A1 (en) | 2001-12-13 | 2004-09-08 | Wockhardt Limited | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| JP2005012561A (ja) | 2003-06-19 | 2005-01-13 | Sony Corp | 画像処理装置、画像処理方法および画像投射装置 |
| CN100471842C (zh) * | 2003-07-24 | 2009-03-25 | 安斯泰来制药有限公司 | 喹诺酮衍生物或其盐 |
| WO2005026145A2 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| WO2005026165A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| DE10343098A1 (de) | 2003-09-18 | 2005-04-14 | Bayer Healthcare Ag | Tetrahydrochinoxaline und ihre Verwendung |
| WO2005049602A1 (en) | 2003-11-18 | 2005-06-02 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| RU2006124559A (ru) | 2003-12-09 | 2008-01-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Производные нафтиридина и применение указанных производныхых в качестве модуляторов мускариновых рецепторов |
| US20090291437A1 (en) * | 2005-11-02 | 2009-11-26 | O'brien Sean | Methods for targeting quadruplex sequences |
| WO2010093341A1 (en) * | 2009-02-10 | 2010-08-19 | Janssen Pharmaceutica N.V. | C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| HUE029734T2 (en) | 2009-12-17 | 2017-03-28 | Merck Sharp & Dohme | Kinolin amide M1 receptor positive allosteric modulators |
| WO2011104322A1 (de) | 2010-02-27 | 2011-09-01 | Bayer Pharma Aktiengesellschaft | Bis-arylverknüpfte aryltriazolone und ihre verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| BR112013000596A2 (pt) | 2010-07-09 | 2019-09-24 | Bayer Intelectual Property Gmbh | piridinas e tiazinas fusionadas e seus usos. |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| CN103360388B (zh) * | 2012-04-10 | 2017-11-14 | 江苏先声药业有限公司 | 5‑氨基‑1，4‑二氢‑1，8‑萘啶衍生物及其药物组合物和用途 |
| CN102964350A (zh) * | 2012-09-20 | 2013-03-13 | 杨文� | 一种7-六氢吡咯并[1,2-a]吡嗪基喹诺酮羧酸衍生物及其在治疗幽门螺杆菌感染应用 |
| CN103183676B (zh) | 2013-03-12 | 2015-04-08 | 中国医学科学院医药生物技术研究所 | 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用 |
| GB201409044D0 (en) | 2014-05-21 | 2014-07-02 | Ucl Business Plc | New compounds |
| MX2017005479A (es) | 2014-11-03 | 2017-07-04 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos. |
| CN107406390B (zh) | 2014-11-17 | 2021-04-16 | 奈吉治疗公司 | 单羧酸转运蛋白调节剂及其用途 |
| CA2990277C (en) | 2015-06-09 | 2021-10-26 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| JP6549735B2 (ja) | 2015-06-09 | 2019-07-24 | アッヴィ・インコーポレイテッド | 核内受容体調節剤 |
| PE20180252A1 (es) * | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
| US10519154B2 (en) | 2016-07-11 | 2019-12-31 | Bayer Pharma Aktiengesellschaft | 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
-
2017
- 2017-06-16 JO JOP/2019/0045A patent/JOP20190045A1/ar unknown
- 2017-09-06 SI SI201730869T patent/SI3512849T1/sl unknown
- 2017-09-06 KR KR1020237006804A patent/KR20230035437A/ko active IP Right Grant
- 2017-09-06 NZ NZ751297A patent/NZ751297A/en not_active IP Right Cessation
- 2017-09-06 CN CN202211273015.6A patent/CN115554294A/zh active Pending
- 2017-09-06 WO PCT/EP2017/072339 patent/WO2018050510A1/de active Application Filing
- 2017-09-06 UA UAA201903730A patent/UA125627C2/uk unknown
- 2017-09-06 CU CU2019000020A patent/CU24618B1/es unknown
- 2017-09-06 PL PL17772322T patent/PL3512849T3/pl unknown
- 2017-09-06 CR CR20190131A patent/CR20190131A/es unknown
- 2017-09-06 DK DK17772322.8T patent/DK3512849T3/da active
- 2017-09-06 HU HUE17772322A patent/HUE056343T2/hu unknown
- 2017-09-06 CN CN202211273380.7A patent/CN115429798A/zh active Pending
- 2017-09-06 RS RS20211093A patent/RS62299B1/sr unknown
- 2017-09-06 MX MX2019003007A patent/MX2019003007A/es unknown
- 2017-09-06 MY MYPI2019001243A patent/MY196473A/en unknown
- 2017-09-06 KR KR1020197007039A patent/KR20190046851A/ko active IP Right Grant
- 2017-09-06 AU AU2017326297A patent/AU2017326297B2/en not_active Ceased
- 2017-09-06 JP JP2019535448A patent/JP7295019B2/ja active Active
- 2017-09-06 TN TNP/2019/000083A patent/TN2019000083A1/en unknown
- 2017-09-06 CN CN201780056605.4A patent/CN109689656B/zh not_active Expired - Fee Related
- 2017-09-06 GE GEAP201715045A patent/GEP20217332B/en unknown
- 2017-09-06 CA CA3036497A patent/CA3036497A1/en active Pending
- 2017-09-06 BR BR112019004982A patent/BR112019004982A2/pt active Search and Examination
- 2017-09-06 MA MA46235A patent/MA46235B1/fr unknown
- 2017-09-06 EP EP17772322.8A patent/EP3512849B1/de active Active
- 2017-09-06 PE PE2019000524A patent/PE20190803A1/es unknown
- 2017-09-06 SG SG11201901973RA patent/SG11201901973RA/en unknown
- 2017-09-06 CN CN202211273001.4A patent/CN115477649A/zh active Pending
- 2017-09-06 LT LTEPPCT/EP2017/072339T patent/LT3512849T/lt unknown
- 2017-09-06 ES ES17772322T patent/ES2887674T3/es active Active
- 2017-09-06 US US16/333,079 patent/US10927109B2/en active Active
- 2017-09-14 UY UY0001037403A patent/UY37403A/es unknown
- 2017-09-14 TW TW106131572A patent/TWI758325B/zh active
-
2019
- 2019-02-28 IL IL265106A patent/IL265106B/en unknown
- 2019-03-12 PH PH12019500535A patent/PH12019500535A1/en unknown
- 2019-03-14 DO DO2019000060A patent/DOP2019000060A/es unknown
- 2019-03-14 CO CONC2019/0002361A patent/CO2019002361A2/es unknown
- 2019-03-14 NI NI201900023A patent/NI201900023A/es unknown
- 2019-03-14 EC ECSENADI201918116A patent/ECSP19018116A/es unknown
- 2019-03-14 CL CL2019000670A patent/CL2019000670A1/es unknown
- 2019-04-12 ZA ZA2019/02325A patent/ZA201902325B/en unknown
-
2021
- 2021-01-28 US US17/161,201 patent/US11472803B2/en active Active
- 2021-01-28 US US17/161,186 patent/US20220089591A1/en not_active Abandoned
- 2021-09-02 CY CY20211100782T patent/CY1124492T1/el unknown
- 2021-09-02 HR HRP20211396TT patent/HRP20211396T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| MX2019012534A (es) | Combinacion de elafibranor o derivados del mismo con un agente anti-ehna, antifibrotico o anticolestasico. | |
| MX2019015311A (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| WO2016134335A3 (en) | Pvrig polypeptides and methods of treatment | |
| BR112017011215A2 (pt) | partículas de distribuição de pró-flavorizante | |
| WO2016060996A3 (en) | Interleukin-15 compositions and uses thereof | |
| WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
| WO2016149501A3 (en) | Modified therapeutic agents and compositions thereof | |
| WO2016007617A3 (en) | Pharmaceutical compounding kit | |
| WO2019240713A3 (en) | Solutions comprising ozonized oil | |
| EP4218736A3 (en) | Compositions comprising 15-hepe | |
| WO2017139664A8 (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| GT201600002A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
| MX2016014564A (es) | Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido. | |
| WO2016046156A8 (de) | Substituierte oxopyridin-derivate | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX2018008645A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX2018002546A (es) | Composiciones que comprenden un compuesto de urolitina. | |
| CR20190131A (es) | 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
| WO2016170124A3 (en) | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior | |
| MX2017012596A (es) | Una composicion farmaceutica y el uso de la misma. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| SG10201811078XA (en) | Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions |